{
  "pmcid": "12484463",
  "sha256": "1a55a91296589433791e7f4db9eaa7b5df1ed721b41f54268bd24a1a1ab4f91d",
  "timestamp_utc": "2025-11-09T23:40:58.083581+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.097849462365595,
    "reading_ease": 25.697329749103943,
    "word_count": 248
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Liposomal Bupivacaine vs. Plain Bupivacaine with Dexamethasone for Postoperative Analgesia in VATS"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "In this double-blind, randomised controlled trial, 90 VATS patients were randomised"
      },
      "Participants": {
        "score": 2,
        "evidence": "The study was conducted at a single center, with recruitment from April 2024 to June 2024."
      },
      "Intervention": {
        "score": 2,
        "evidence": "90 VATS patients were randomised to receive either 93 mg liposomal bupivacaine with 25 mg plain bupivacaine or 105 mg plain bupivacaine with 5 mg dexamethasone."
      },
      "Objective": {
        "score": 1,
        "evidence": "This trial assessed whether liposomal bupivacaine provides non-inferior analgesia compared to plain bupivacaine with dexamethasone via rhomboid intercostal block (RIB)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the area under the curve (AUC) of the 48-hour resting pain numeric rating scale (NRS)."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated with allocation concealment"
      },
      "Blinding": {
        "score": 2,
        "evidence": "both patients and clinicians were blinded"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "90 VATS patients were randomised"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Liposomal bupivacaine was non-inferior to plain bupivacaine with dexamethasone, with a 48-hour NRS AUC of 105.5 ± 13.6 vs. 113.1 ± 16.3"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "with a 48-hour NRS AUC of 105.5 ± 13.6 vs. 113.1 ± 16.3 (mean difference -7.6; 95% CI -13.9 to -1.2)"
      },
      "Harms": {
        "score": 1,
        "evidence": "Safety profiles were comparable, with no significant differences in adverse events such as postoperative nausea and vomiting."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial Registration: ClinicalTrials.gov NCT06392191"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 21,
    "max_score": 25
  }
}